Casino Bonus Sans DepotTous Les Sites De Paris Sportifs BelgiqueSites De Paris Sportifs Autorisés En BelgiqueSite Paris Sportif BelgiqueCasino En Ligne 2026
Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

About Age-Related Macular Degeneration (AMD)

Age-related macular degeneration (AMD) is a progressive disease affecting the retinal cells in the macula, the region of the eye responsible for central vision.

"Wet" AMD is an advanced form of AMD where blood vessels begin to invade the cellular space between layers of cells in the retina. These new blood vessels are often leaky, which results in fluid and blood in the retina and causes vision loss. While wet AMD represents only 10% of the number of cases of AMD overall, it is responsible for 90% of the AMD related severe vision loss. Of untreated patients who are not already partially sighted or blind, over half will become partially sighted or blind within three years. Each year, approximately 150,000 to 200,000 Americans develop wet AMD, with the number expected to grow due to the aging US population.

Normal Vision AMD Vision
Normal Retina Wet AMD

More great reads

Avalanche Biotechnologies, Inc. Names Paul B. Cleveland as CEO

MENLO PARK, Calif., Nov. 20, 2015 -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a biopharmaceutical company committed to improving or preserving the sight of people suffering from serious eye diseases with an unmet medical need, today announced the appointment of Paul B. Cleveland to chief executive officer (CEO) and to the Board of Directors effective December 9. He also will serve as principal financial officer of Avalanche on an interim basis. Mr. Cleveland, previously the chief executive officer of Celladon Corporation, brings more than 20 years of leadership experience to Avalanche, including management and operational experience across the biotechnology industry. This includes positions at multiple public biotechnology companies, including CEO, president, chief financial officer and Board member as well as chief operating officer at a venture capital firm. Subsequent to December 9, Hans P. Hull who has been serving as interim CEO of Avalanche since July, will return to his previous role of senior vice president of business operations.

Read More

Read All Avalanche News

@Avalanchebio Twitter Feed

Connect with Avalanche Biotech on Twitter